Seizures
There is some clinical evidence that stimulants may lower the convulsive threshold in patients with prior history of seizure, in patients with prior EEG abnormalities in absence of seizures, and very rarely, in patients without a history of seizures and no prior EEG evidence of seizures. In the presence of seizures, the drug should be discontinued.
Visual Disturbance
Difficulties with accommodation and blurring of vision have been reported with stimulant treatment.
PRECAUTIONS

General:
The least amount of Vyvanse feasible should be prescribed or dispensed at one time in order to minimize the possibility of overdosage. Vyvanse should be used with caution in patients who use other sympathomimetic drugs. Tics: Amphetamines have been reported to exacerbate motor and phonic tics and Tourette's syndrome. Therefore, clinical evaluation for tics and Tourette's syndrome in children and their families should precede use of stimulant medications. Information lor Patients: Amphetamines may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or vehicles; the patient should therefore be cautioned accordingly. Presenters or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated with treatment with lisdexamfetamine and should counsel them in its appropriate use. A patient Medication Guide is available for Vyvanse. The preserver or health professional should instruct patients, their families, and their caregivers to read the Medication Guide and should assist them in understanding its contents. Patients should be given the opportunity to discuss the contents of the Medication Guide and to obtain answers to any questions they may have The complete text of the Medication Guide is reprinted at the end of this document.
Drug Interactions:
Urinary acidifying agents -These agents (ammonium chloride, sodium acid phosphate, etc.] increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion. Both groups of agents lower blood levels and efficacy of amphetamines. Adrenergic blockers-Adrenerglc blockers are inhibited by amphetamines. Antidepressants, tricyclic-Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents; damphetamine with desipramine or protrlptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. MAO inhibitors-MAO! antidepressants, as well as a metabolite of furazolidone, slow amphetamine metabolism. This slowing potentiates amphetamines, increasing their effect on the release of norepinephrine and other monoamines from adrenergic nerve endings; this can cause headaches and other signs of hypertensive crisis. A variety of toxic neurological effects and malignant hyperpyrexia can occur, sometimes with fatal results. Antihistamines-Amphetamines may counteract the sedative effect of antihistamines. Antibypertansives-Amphetamines may antagonize the hypotensive effects of antihypertensives. Chlorpromazine-Crilorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.
Ethosuximide-Amphetamines may delay intestinal absorption of ethosuximide.
Haloperidol-Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines. Lithium carbonate-The anorectic and stimulatory effects of amphetamines may be inhibited by lithium carbonate. Mepehdine-Amphetamines potentiate the analgesic effect of meperidine.
Methenamine therapy-Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in methenamine therapy. Norepinephrine-Amphetamines enhance the adrenergic effect of norepinephrine. Phenobarbitai-Amphetamines may delay intestinal absorption of phenobarbital; co-administration of phenobarbital may produce a synergistic anticonvulsant action. Pftenyto/n-Amphetamines may delay intestinal absorption of phenytoin; co-administration of phenytoin may produce a synergistic anticonvulsant action Propoxyphene-In cases of propoxyphene overdosage, amphetamine CMS stimulation is potentiated and fatal convulsions can occur. Veratmm alkaloids-Amphetamines inhibit the hypolensive effect of veratrum alkaloids. Drug/Laboratory Test Interactions: Amphetamines can cause a significant elevation in plasma corticosteroid levels. This increase is greatest in the evening. Amphetamines may interfere with urinary steroid determinations. Carcinogenesis/Mutagenesis and Impairment of Fertility: Carcinogenicity studies of lisdexamfetamine have not been performed. No evidence of carcinogenicity was found in studies in which d, l-amphetamine (enantiomer ratio of 1:1) was administered to mice and rats in the diet for 2 years at doses of up to 30 mg/kg/day in male mice, 19 mg/kg/day in female mice, and 5 mg/kg/day in male and female rats. Lisdexamfetamine dimesylate was not clastogenic in the mouse bone marrow micronucleus test in vivo and was negative when tested in the F. coli and S. typhimurium components of the Ames test and in the L5178Y/TK + " mouse lymphoma assay in vitro. Amphetamine (d to I enantiomer ratio of 3:1) did not adversely affect fertility or early embryonic development in the rat at doses of up to 20 mg/kg/day. Pregnancy: Pregnancy Category C, Reproduction studies of lisdexamfetamine have not been performed Amphetamine (d to I enantiomer ratio of 3:1) had no apparent effects on embryofetal morphological development or survival when orally administered to pregnant rats and rabbits throughout the period of organogenesis at doses of up to 6 and 16 mg/kg/day, respectively. Fetal malformations and death have been reported in mice following parenteral administration of dextroamphetamine doses of 50 mg/kg/day or greater to pregnant animals. Administration of these doses was also associated with severe maternal toxicity. A number of studies in rodents indicate that prenatal or early postnatal exposure to amphetamine (d-or d,l-\ at doses similar to those used clinically can result in long term neurochemical and behavioral alterations. Reported behavioral effects include learning and memory deficits, altered locomotor activity, and changes in sexual function. There are no adequate and well-controlled studies in pregnant women. There has been one report of severe congenital bony deformity, tracheo-esophageal fistula, and anal atresia (vater association) in a baby bom to a woman who took dextroamphetamine sulfate with lovastatin during the first trimester of pregnancy. Amphetamines should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Nonteratogenic Effects: Infants born to mothers dependent on amphetamine have an increased risk of premature delivery and low birth weight. Also, these infants may experience symptoms of withdrawal as demonstrated by dysphoria, including agitation, and significant lassitude. Usage in Nursing Mothers: Amphetamines are excreted in human milk. Mothers taking amphetamines should be advised to retrain from nursing. Pediatric Use: Vyvanse is indicated for use in children aged 6 to 12 years. A study was conducted in which juvenile rats received oral doses of 4,10, or 40 mg/kg/day of lisdexamfetamine from day 7 to day 63 of age. These doses are approximately 0.3, 0.7, and 3 times the maximum recommended human daily dose ol 70 mg on a mg/nV basis. Dose-related decreases in food consumption, bodyweight gain, and crown-rump length were seen, after a four week drug-free recovery period bodyweights and crown-rump lengths had significantly recovered in females but were still substantially reduced in males. Time to vaginal opening was delayed in females at the highest dose, but there were no drug effects on fertility when the animals were mated beginning on day 85 of age. In a study in which juvenile dogs received lisdexamfetamine for 6 months beginning at 10 weeks of age, decreased bodyweight gain was seen at all doses tested (2,5, and 12 mg/kg/day, which are approximately 0.5,1, and 3 times the maximum recommended human daily dose on a mgW basis). This effect partially or fully reversed during a four week drug-free recovery period. Use in Children under Six Years of Age: Lisdexamfetamine dimesylate has not been studied in 3-5 year olds. Long-term effects of amphetamines in children have not been well established. Amphetamines are not recommended for use in children under 3 years of age. Geriatric Use: Vyvanse has not been studied in the geriatric population.
ADVERSE EVENTS
The premarketing development program for Vyvanse included exposures in a total of 404 participants in clinical trials (346 pediatric patients and 56 healthy adult subjects). Of these, 348 pediatric patients (ages 6 to 12) were evaluated in two controlled clinical studies (one parallel-group and one crossover), one open-label extension study, and one single-dose clinical pharmacology study. The information included in this section is based on data from the 4-week parallel-group controlled clinical trial in pediatric patients with ADHD. Adverse reactions were assessed by collecting adverse events, results of physical examinations, vital signs, weights, laboratory analyses, and ECGs. Adverse events during exposure were obtained primarily by general inquiry and recorded by clinical investigators using terminology of their own choosing. Consequently, it is not possible to provide a meaningful estimate of the proportion of individuals experiencing adverse events without first grouping similar types of events into a smaller number of standardized event categories. In the tables and listings that follow, MedRA terminology has been used to classify reported adverse events. The stated frequencies of adverse events represent the proportion of individuals who experienced, at least once, a treatmenf-emergent adverse event of the type listed. Adverse events associated with discontinuation ot treatment: Ten percent (21/218) of Vyvanse-treated patients discontinued due to adverse events compared to 1% (1/72] who received placebo. The most frequent adverse events leading to discontinuation and considered to be drug-related (i.e., leading to discontinuation in at least 1% of Vyvanse-treated patients and at a rate at least twice that of placebo] were ECG voltage criteria for ventricular hypertrophy, tic, vomiting, psychomolor hyperactivity, insomnia, and rash (2/218 each; 1%]. Adverse events occurring in a controlled trial: Adverse events reported in a 4-week clinical trial in pediatric patients treated with Vyvanse or placebo are presented in the table below. The prescribe/ should be aware that these figures cannot be used to predict the incidence of adverse events in the course of usual medical practice where patient characteristics and other factors differ from those which prevailed in the clinical trials. Similarly, the cited frequencies cannot be compared with figures obtained from other clinical investigations involving different treatments, uses, and investigators. The cited figures, however, do provide the prescribing physician with some basis for estimating the relative contribution of drug and non-drug factors to the adverse event incidence rate in the population studied. The following adverse events that occurred in at least 5% of the Vyvanse patients and at a rate twice that of the placebo group (Table 1] : Upper abdominal pain, decreased appetite, dizziness, dry mouth, irritability, insomnia, nausea, vomiting, and decreased weight.
The following additional adverse reactions have Amphetamines have been extensively abused. Tolerance, extreme psychological dependence, and severe social disability have occurred. There are reports of patients who have increased the dosage to levels many times higher than recommended. Abrupt cessation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on the sleep EEG. Manifestations of chronic intoxication with amphetamines may include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. The most severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.
Human Studies
In a human abuse liability study, when equivalent oral doses of 100 mg lisdexamfetamine dimesylate and 40 mg immediate release d-amphetamine sulfate were administered to individuals with a history of drug abuse, lisdexamfetamine 100 mg produced subjective responses on a scale of "Drug Liking Effects" "Amphetamine Effects", and "Stimulant Effects" that were significantly less than d-amphetamine immediate release 40 mg. However, oral administration of 150 mg lisdexamfetamine produced increases in positive subjective responses on these scales that were statistically indistinguishable from the positive subjective responses produced by 40 mg of oral immediate-release d-amphetamine and 200 mg of diethylpropion (C-IV). Intravenous administration of 50 mg lisdexamfetamine to individuals with a history of drug abuse produced positive subjective responses on scales measuring "Drug Liking", "Euphoria", "Amphetamine Effects", and "Benzedrine Effects" that were greater than placebo but less than those produced by an equivalent dose (20 mg) of intravenous d-amphetamine.
Animal Studies
In animal studies, lisdexamfetamine produced behavioral effects qualitatively similar to those of the CNS stimulant d-amphetamine. In monkeys trained to self-administer cocaine, intravenous lisdexamfetamine maintained self-administration at a rate that was statistically less than that for cocaine, but greater than that of placebo. OVERDOSAGE Individual response to amphetamines varies widely. Toxic symptoms may occur idiosyncratically at low doses. Symptoms: Manifestations of acute overdosage with amphetamines include restlessness, tremor, hyperreflexia, rapid respiration, confusion, assaultiveness, hallucinations, panic states, hyperpyrexia and rhabdomyolysis. Fatigue and depression usually follow the central nervous system stimulation. Cardiovascular effects include arrhythmias, hypertension or hypoten Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal convulsions and coma. Treatment: Consult with a Certified Poison Control Center for up to date guidance and advice. Management of acute amphetamine intoxication is largely symptomatic and includes gastric lavage, administration of activated charcoal, administration of a cathartic and sedation. Experience with hemodialysis or peritoneal dialysis is inadequate to permit recommendation in this regard. Acidification of the urine increases amphetamine excretion, but is believed to increase risk of acute renal failure if myoglobinuria is present. If acute severe hypertension complicates amphetamine overdosage, administration of intravenous phentolamine has been suggested. However, a gradual drop in blood pressure will usually result when sufficient sedation has been achieved. Chlorpromazine antagonizes the central stimulant effects of amphetamines and can be used to treat amphetamine intoxication. The prolonged release of Vyvanse in the body should be considered when treating patients with overdose. 
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Dates to Remember: • EFFEXOR XR is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs).
• Adult and pediatric patients taking antidepressants can experience worsening of their depression and/or the emergence of suicidality. All patients should be monitored appropriately and observed closely for clinical worsening and suicidality, especially at the beginning of drug therapy, or at the time of increases or decreases in dose. Anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, and mania have been reported and may represent precursors to emerging suicidality. Stopping or modifying therapy should be considered especially when symptoms are severe, abrupt in onset, or not part of presenting symptoms.
with EFFEXOR XR
: Patients currently on an SSRI should be evaluated following an adequate trial. »Mydriasis has been reported in association with venlafaxine; therefore, patients with raised intraocular pressure or those at risk of acute narrowangle glaucoma (angle-closure glaucoma) should be monitored. * Abrupt discontinuation or dose reduction has been associated with discontinuation symptoms. Patients should be counseled on possible discontinuation symptoms and monitored while discontinuing the drug; the dose should be tapered gradually.
ONCE-DAILY
VENLAFAXINE HCI
EFFEXOR XR
The change they deserve. showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 18-24) with MDD and other psychiatric disorders. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction with antidepressants compared to placebo in adults aged 65 and older. The pooled analyses of placebo-controlled trials in children and adolescents with MDD, obsessive-compulsive disorder (OCD), or other psychiatric disorders included a total of 24 short-term trials of 9 antidepressant drugs in over 4,400 patients. The pooled analyses of placebo-controlled trials in adults with MDD or other psychiatric disorders included a total of 295 short-term trials (median duration of 2 months) of 11 antidepressant drugs in over 77,000 patients. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. placebo), however, were relatively stable within age strata and across indications. These risk differences (drugplacebo difference in the number of cases of suicidality per 1,000 patients treated) are provided in Table 1 of the full prescribing information. No suicides occurred in any of the pediatric trials. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide. It is unknown whether the suicidality risk extends to longer-term use. However, there is substantial evidence from placebo-controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression. All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either Increases or decreases. Anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania have been reported in adult and pediatric patients being treated with antidepressants for MDD and other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms (see PRECAUTIONS and DOSAGE AND ADMINISTRATION). Families and caregivers of patients being treated with antidepressants for MDD or other indications, both psychiatric and nonpsychiatric, should be alerted about the need to monitor patients for the emergence of agitation, irritability, unusual changes in behavior, and the other symptoms described above, as well as the emergence of suicidality, and to report such symptoms immediately to health care providers. Such monitoring should Include daily observation by families and caregivers. Prescriptions for EffexorXR should be written for the smallest quantity of capsules consistent with good patient management, in order to reduce the risk of overdose. Screening Patients for Bipolar Disorder: A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represents such a conversion is unknown. Prior to initiating antidepressant treatment, patients with depressive symptoms should be screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. Effexor XR is not approved for use in treating bipolar depression. Abrupt discontinuation or dose reduction of venlafaxine at various doses is associated with new symptoms, the frequency of which increased with increased dose level and longer duration of treatment. Symptoms include agitation, anorexia, anxiety, confusion, coordination impaired, diarrhea, dizziness, dry mouth, dysphoric mood, emotional lability, fasciculation, fatigue, headaches, hypomania, insomnia, irritability, lethargy, nausea, nervousness, nightmares, seizures, sensory disturbances (e.g., paresthesias such as electric shock sensations), somnolence, sweating, tinnitus, tremor, vertigq, and vomiting. Monitor patients when discontinuing treatment. A gradual reduction in the dose rather than abnjpt'cessation is recommended. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, consider resuming the previously prescribed dose. Subsequently, continue decreasing the dose at a more gradual rate. Insomnia and Nervousness. Treatment-emergent insomnia and nervousness have been reported. In Phase 3 trials, insomnia led to drug discontinuation in 1% of both depressed patents and Panic Disorder (PD) patients and in 3% of both Generalized Anxiety Disorder (GAD) and Social Anxiety Disorder (SAD) patients. Nervousness led to drug discontinuation in 0.9% of depressed patients, in 2% of GAD patients, and in 0% of SAD and PD patients. Changes in Weight. Adult Patients In short-term MDD trials, 7% of Effexor XR patients had >5% loss of body weight and 0.1 % discontinued for weight loss. In 6-month GAD studies, 3% of Effexor XR patients had >7% loss of body weight, and 0.3% discontinued for weight loss in 8-week studies. In 12-week SAD trials, 3% of Effexor XR patients had >7% loss of body weight and no patients discontinued for weight loss. In 12-week PD trials, 3% of Effexor XR patients had >7% loss of body weight, and no patients discontinued for weight loss. The safely and efficacy of venlafaxine in combination with weight loss agents, including phentermine, have not been established. Coadministrafion of Effexor XR and weight loss agents is not recommended. Effexor XR is not indicated for weight loss alone or in combination with other products. Pediatric Patients: Weight loss was seen in patients aged 6-17 receiving Effexor XR. More Effexor XR patients than placebo patients experienced weight loss of at least 3.5% in both MDD and GAD studies (18% of Effexor XR patients vs. 3.6% of placebo patients; P<0.001) and the SAD study (47% of Effexor XR patients vs. 14% of placebo patients; P<0.001).
Weight loss was not limited to patients with treatment-emergent anorexia (decreased appetite). Children and adolescents in a 6-month MDD study had increases in weight less than expected based on data from age-and sexmatched peers. The difference between observed and expected weight gain was larger for children <12 years old than for adolescents >12 years old. Changes in Height Pediatric Patients: In 8-week GAD studies, Effexor XR patients aged 6-17 grew an average of 0.3 cm (n=122), while placebo patients grew an average of 1.0 cm (n=132); ft=0.041. This difference in height increase was most notable in patients <12. In 8-week MDD studies, Effexor XR patients grew an average of 0.8 cm (n=146), while placebo patients grew an average of 0.7 cm (n=147). During the 16-week, placebocontrolled SAD study, both the Effexor XR (n=109) and the placebo (n=112) patients grew an average of 1.0 cm. In the 6-month MDD study, children and adolescents had height increases less than expected based on data from ageand sex-matched peers. The difference between observed and expected growth rates was larger for children <12 years old than for adolescents >12 years old. Changes in Appetite: Adult Patients. Treatment-emergent anorexia was more commonly reported for Effexor XR (8%) than placebo (4%) patients in MDD studies. The discontinuation rate for anorexia was 1.0% in MDD studies. Treatment-emergent anorexia was more commonly reported for Effexor XR (8%) than placebo (2%) patients in GAD studies. The discontinuation rate for anorexia was 0.9% for up to 8 weeks in GAD studies. Treatment-emergent anorexH was more commonly reported for Effexor XR (20%) than placebo (2%) patients in SAD studies. The discontinuation rate for anorexia was 0.4% for up to 12 weeks in SAD studies. Treatmentemergent anorexia was more commonly reported for Effexor XR (8%) than placebo (3%) patients in PD studies. The discontinuation rate for anorexia was 0.4% for EffexorXR patients in 12-week PD studies. Pediatric Patients. Decreased appetite was seen in pediatric patients receiving Effexor XR. In GAD and MDD trials, 10% of Effexor XR patients aged 6-17 for up to 8 weeks and 3% of placebo patients had treatment-emergent anorexia. None of the patients receiving Effexor XR discontinued for anorexia or weight loss. In the placebo-controlled trial for SAD, 22% and 3% of patients aged 8-17 treated for up to 16 weeks with Effexor XR and placebo, respectively, reported treatmentemergent anorexia (decreased appetite). The discontinuation rates for anorexia were 0.7% and 0.0% for patients receiving Effexor XR and placebo, respectively: the discontinuation rates for weight loss were 0.7% for patients receiving either Effexor XR or placebo. Activation ofMania/Hypomania Mania or hypomania has occurred during short-term depression and PD studies. As with all drugs effective in the treatment of MDD, Effexor XR should be used cautiously in patients with a history of mania. Families and caregivers of patients should be advised to look for the emergence of such symptoms on a day-to-day basis, since changes may be abrupt. Such symptoms should be reported to the patient's prescriber or health professional, especially if they are severe, abrupt in onset or were not part of the patient's presenting symptoms. Symptoms such as these may be associated with an increased risk for suicidal thinking and behavior and indicate a need for very ctose monitoring and possibly changes in the medication. Caution patients 1) about operating hazardous machinery, including automobiles, until they are reasonably sure that venlafaxine does not adversely affect their abilities; 2) to avoid alcohol while taking Effexor XR; and 3) about the risk of serotonin syndrome with the concomitant use of Effexor XR and tnptans, tramadol, tryptophan supplements, or other serotonergic agents. Patients should be advised to notify their physician 1) if they become pregnant or intend to become pregnant during therapy, or if they are nursing; 2) about other prescription or over-the-counter drugs, including herbal preparations and nutritional supplements they are taking or plan to take; 3) if they develop a rash, hives, or related allergic phenomena; or 4) if they have a history of glaucoma or increased intraocular pressure. Laboratory TestsNo specific laboratory tests are recommended. Drug Interactions-Alcohol: A single dose of ethanol had no effect on the pharmacokinetics (PK) of venlafaxine or O-desmethytvenlafaxine (ODV), and venlafaxine did not exaggerate the psychomotor and psychometric effects induced by ethanol. Cimetidine: Use caution when administering venlafaxine with cimetidine to patients with pre-existing hypertenston or hepatic dysfunction, and the elderly. Diazepam. A single dose of diazepam did not appear to affect the PK of either venlafaxine or ODV. Venlafaxine did not have any effect on the PK of diazepam or its active metabolite, desmethyldiazepam, or affect the psychomotor and psychometric effects induced by diazepam. Haloperidot. Venlafaxine decreased total oral-dose clearance of haloperidol, resulting in a 70% increase in haloperidol AUC. The haloperidol Cm, increased 88%, but the haloperidol elimination half-life was unchanged. Ulhiunr. A single dose of lithium did not appear to affect the PK of either venlafaxine or ODV. Venlafaxine had no effect on the PK of lithium. Drugs Highly Bound to Plasma Proteins. Venlafaxine is not highly bound to plasma proteins; coadministration of Effexor XR with a highly protein-bound drug should not cause increased free concentrations of the other drug. Drugs That inhibit Cytochrome PASO Isoenzymes. CYP2D6 Inhibitors: Venlafaxine is metabolized to Its active metabolite, ODV, by CYP2D6. Drugs inhibiting this isoenzyme have the potential to increase plasma concentrations of venlafaxine and decrease concentrations of ODV. No dosage adjustment is required when venlafaxine is (^administered with a CYP2D6 inhibitor. Concomitant use of venlafaxine with drug treatments) that potentially inhibits both CYP2D6 and CYP3A4, the primary metabolizing enzymes for venlafaxine, has not been studied. Use caution if therapy includes venlafaxine and any agentls) that produces simultaneous inhibition of these two enzyme systems. Drugs Metabolized by Cytochrome P4S0 Isoenzymes. Venlafaxine is a relatively weak inhibitor of CYP2D6. Venlafaxine did not inhibit CYP1A2 and CYP3A4, CYP2C9 (in vitro), or CYP2C19. Imipramine. Venlafaxine did not affect the PK of imipramine and 2-0H-imipramine. However, desipramine AUC, C™ and Can increased by -35% in the presence of venlafaxine. The 2-0H-desipramine AUCs increased by 2.5-4.5 fold. Imipramine did not affect the PK of venlafaxine and ODV. Risperidone: Venlafaxine slightly inhibited the CYP2D6-mediated metabolism of risperidone to its active metabolite, 9-hydroxyrisperidone, resulting in a -32% increase in risperidone AUC. Venlafaxine coadministration did not significantly alter the PK profile of the total active moiety (risperidone plus 9-hydroxyrisperidone). CYP3A4: Venlafaxine did not inhibit CYP3A4 in vitro and in vivo. Indinavir. In a study of 9 healthy volunteers, venlafaxine administration resulted in a 28% decrease in the AUC of a single dose of indinavir and a 36% decrease in indinavir Cmax. Indinavir did not affect the PK of venlafaxine and ODV. CYP1A2: Venlafaxine did not inhibit CYP1A2 in vitro and in vivo. CYP2C9: Venlafaxine did not inhibit CYP2C9 in vitro. In vivo, venlafaxine 75 mg by mouth every 12 hours did not alter the PK of a single 550-mg dose of tolbutamide or the CYP2C9-mediated formation of 4-hydroxy-toibutamide. CYP2C19: Venlafaxine did not inhibit the metabolism of diazepam, which is partially metabolized by CYP2C19 (see Diazepam above). MAOIs See CONTRAINDICATIONS and WARNINGS. CNS-Active Drugs: Use caution with concomitant use of venlafaxine and other CNS-active drugs. Serotonergic Drugs and Tnptans (see WARNINGS: Serotonin Syndrome): Based on the mechanism of action of Effexor XR and the potential for serotonin syndrome, caution is advised when Effexor XR is ^administered with other drugs that may affect the serotonergk; neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St John's wort. If concomitant treatment of Effexor XR with these drugs is clinically warranted, careful observation of the patient is advteed, particuiariy during treatment initiation and dose increases. The concomitant use of Effexor XR with tryptophan supplements is not recommended. Bectnxomulsne Therapy (ECT) There are no clinical data establishing the benefit of ECT combined with Effexor XR treatment. Carctnogenesis, Mutagenests, Impairment of Fertility-Cardnogenesls: There was no increase in tumors in mice and rats given up to 1.7 times the maximum recommended human dose (MRHD) on a mg/nf basis. Mutagenesis Venlafaxine and ODV were not mutagenic in the Ames reverse mutation assay in Salmonella bacteria or the CHC7HGPRT mammalian cell forward gene mutation assay. Venlafaxine was not clastogenic in several assays. ODV elicited a clastogenic response in the in vivo chromosomal aberration assay in rat bone marrow. Impairment of Fertility: No effects on reproduction or fertility in rats were noted at oral doses of up to 2 times the MRHD on a mg'm-1 basis. Pregnancy-Temtogenk effects-Pregnancy Category C. Reproduction studies in rats given 2.5 times, and rabbits given 4 times the MRHD (mg/m ! basis) revealed no malformations in offspring. However, in rats given 2.5 times the MRHD, there was a decrease in pup weight, an increase in stillborn pups, and an Increase in pup deaths during the first 5 days of lactation when dosing began during pregnancy and continued until weaning. There are no adequate and well-controlled studies in pregnant women; use Effexor XR during pregnancy only if dearly needed. Nonteratogenk Effects: Neonates exposed to Effexor XR late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding.
Complications can arise immediately upon delivery. Reports include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. This is consistent with a direct toxic effect of SNRIs or a drug discontinuation syndrome. In some cases, it is consistent with serotonin syndrome. When treating a pregnant woman with Effexor XR during the third trimester, carefully consider the potential risks and benefits of treatment and consider tapering Effexor XR in the third trimester. Labor, Delivery, Nursing-The effect on labor and delivery in humans is unknown. Venlafaxine and ODV have been reported to be excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from Effexor XR, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother pediatric Use-Safety and effectiveness in the pediathc population have not been established (see BOX WARNING and WARNINGS: Clinical Worsening and Suicide Risk) . No studies have adequately assessed the impact of Effexor XR on growth, development and maturation of children and adolescents. Studies suggest Effexor XR may adversely affect weight and height (see PRECAUTMNS-General, Changes in Height and Changes in Weight) . Should the decision be made to treat a pediatric patient with Effexor XR, regular monitoring of weight and height is recommended during treatment, parttculaity if long term. The safety of Effexor XR for pediatric patients has not been assessed for chronic treatment >6 months. In studies in patients aged 6-17, blood pressure and cholesterol increases considered to be clinically relevant were similar to that observed in adult patients. The precautions for adults apply to pediatric patients. Geriatric U s eNo overall differences in effectiveness or safety were observed between geriatric and younger patients. Respiratory system -Frequent: cough increased, dyspnea; Infrequent: asthma, chest congestion, epistaxis, hypervenf lation, laryngismus, laryngitis, pneumonia, voice alteration; Rare: atelectasis, hemoptysis, hypoventilation, hypoxia, larynx edema, pleurisy, pulmonary embolus, sleep apnea. Skin and appendages -Frequent pruritus; Infrequent: acne, alopecia, contact dermatitis, dry skin, eczema, maculopapular rash, psoriasis, urticaria; Rare: brittle nails, erythema nodosum, exfoliative dennatitis, lichenoid dermatitis, hair discoloration, skin discoloration, funjnculosis, hirsutism, leukodenma, miliaria, petechial rash, pruritJc rash, pustular rash, vesiculobullous rash, seborrtiea, skin atrophy, skin hypertrophy, skin striae, sweating decreased. Special senses -Frequent abnormality of accommodation, mydriasis, taste perversion; Infrequent: conjunctivitis, diplopia, dry eyes, eye pain, hyperacusis, otfUs media, parosmia, photophobia, taste loss, visual field defect Rare: blepharitis, cataract chromatopsia, conjunctival edema, comeal lesion, deafness, exopnthalmos, eye hemorrhage, glaucoma, retinal hemorrhage, subconjuncM hemorrhage, keratrtis, labyrinthitis, miosls, papilledema, decreased pupillary reflex, otrrjs extema, scleritJs, uveitis. Unwenital system -Frequent prostate disorder (prostatitis, enlarged prostate, and prostate irritability), urination impaired; Infrequent albuminuria, amenontiea, cystitis, dysuria, hematuria, kidney calculus, kidney pain, leukorrhea, menorrhagia, metrorrhagia, nocturia, breast pain, polyuria, pyuria, urinary incontinence, urinary retention, urinary urgency, vaginal hemorrhage, vaginitis: Rare: abortion, anuria, balanitis, bladder pain, breast discharge, breast engorgement, breast enlargement, endometriosis, female lactation, fibrocystic breast, calcium crystalluria, cervicitis, orchitls, ovarian cyst, prolonged erection, gynecomastia (male), hypomenorrtiea, kidney function abnormal, mastitis, menopause, pyelonephritis, oliguria, salpingils. urollthiasis, uterine hemorrhage, uterine spasm, vaginal dryness. Postmarketing Reports: agranulocytosis, anaphylaxis, aplastc anemia, catatonia, congenital anomalies, CPK increased, deep vein thrombophlebitis, delirium, EKG abnormalities such as QT prolongation; cardiac arrhythmias including atrial fibrillation, supraventricular tachycardia, ventricular extrasystoles, and rare reports of ventricular fibrillation and ventricular tachycardia, including torsades de pointes; epidermal necrosis/Stevens-Johnson syndrome, erythema multjforme, extrapyramidal symptoms (including dyskinesia and tardfve dyskinesia), angle-closure glaucoma, hemorrhage (including eye and gastrointestinal bleeding), hepatic events (including GGT elevation; abnormalities of unspecified liver function tests; liver damage, necrosis, or failure; and fatty liver), interstitial lung disease, involuntary movements, LDH increased, neuroleptic malignant syndrome-like events (including a case of a 10-year-old who may have been taking methylphenidate, was treated and recovered), neutropenfl, night sweats, pancreatitis, pancytopenia, panic, prctacln increased, renal failure, itiabdomyolysis, serotonin syndrome, shock-like electrical sensations or tinnitus (in some cases, subsequent to the discontinuation of venlafaxine or tapering of dose), and SIADH (usually in the elderly). Elevated clozapine levels that were temporally associated with adverse events, including seizures, have been reported following the addition of venlafaxine. Increases in prothrombin time, partial thromboplastin time, or INR have been reported when venlafaxine was given to patients on warfarin therapy. DRUG ABUSE AND DEPENDENCE: Effexor XR is not a controlled substance. Evaluate patients carefully for history of drug abuse and observe such patients closely for signs of misuse or abuse. OVERDOSAGE: The most commonly reported events in overdosage include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, seizures, and vomiting. Electrocardiogram changes (eg, prolongation of QT interval, bundle branch block, QftS prolongation), ventricular tachycardia, bradycardia, hypotension, rhabdomyolysis, vertigo, liver necrosis, serotonin syndrome, and death have been reported. Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but tower than that for tricyclic antidepressants. Epidemioioglcal studies have shown that venlafaxine-treated patients have a higher pre-existing burden of suicide risk factors than SSRI-treated patients. The extent to which the finding of an Increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage as opposed to some charactetlsttcis) of venlafaxine-treated patients is not clear. Treatment should consist of those general measures employed in the management of overdosage with any antidepressant Ensure an adequate airway, oxygenalon and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large bore orogastric tube with appropriate airway protection, if needed, may be indicated If performed soon after ingeston or in symptomatic patients. Activated charcoal should be administered. Due to the large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. No specific antidotes for venlafaxine are known. In managing overdosage, consider the possibility of multiple drug involvement. Consider contacting a poison control center for additional information on the treatment of overdose. 
CME QUIZ
638 The quiz is CME-accredited by the Mount Sinai School of Medicine for 3.0 credit hours.
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